Methods for the gene therapy of benign prostatic hyperplasia and medical agents therefore

摘要

Disclosed are 1) gene medical agents (Gene Therapeutic Drugs) for the treatment of benign prostatic hyperplasia (BPH) and 2) treatment methods using them such as iTUMAP (TransUrethral Molecular Ablation of Prostate)/i and iTRMAP(TransRectal Molecular Ablation of Prostate)/i. The gene medical agents comprise structural genes able to cause the apoptosis of BPH cells, in combination with regulator genes able to guide the expression of the structural genes targetting specifically on BPH tissues, in carriers. When being administered to lesion foci of BPH tissues, the gene medical agents allow the selective elimination of BPH cells and also prostatic cancer cells developed concurrently that could be the another important merit of this invention. In treating, the carriers are administered directly to the tumor cells of BPH via a transurethral route i(TUMAP)/i or a transrectal route i(TRMAP)/i. This novel, non-invasive method allows BPH tissues to be selectively removed with ease without any side effects such as pain, hemorrhage, etc.